FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313502622> ?p ?o ?g. }

• W4313502622 endingPage "6" @default.
• W4313502622 startingPage "6" @default.
• W4313502622 abstract "Redox disbalance in placental cells leads to the hyperproduction of reactive oxygen species (ROS), it mediates the dysregulation of the maternal immune tolerance to a semi-allogenic fetus, inducing pro-inflammatory reactions, and it plays a central role in perinatal complications and neonatal disease programming. Microvesicles, which provide transplacental communication between a mother and fetus, contain microRNAs (miRNAs) that are sensitive to oxidative stress (OS) mediators and can control the balance of ROS production and utilization in target cells. In the context of this paradigm, we evaluated the markers of redox balance—MDA and 4-HNE for OS and GPx, and SOD, CAT, and GSH for the antioxidant system in the cord blood plasma of newborns diagnosed with fetal growth restriction (FGR)—by using polarography, spectrophotometry, and Western blotting. The expression of miRNAs associated with OS, immune and inflammatory responses in the blood plasma of newborns with intrauterine pneumonia (IP), neonatal sepsis (NS) and respiratory distress syndrome (RDS) was evaluated by a quantitative RT-PCR. Significant differences in the MDA level and reduced GPx and CAT activity were co-found for early-onset FGR (i.e., <34 gestational age). Significant correlations were found with a low birth weight by Apgar scores with reduced levels of antioxidant enzymes. Indeed, the level of OS markers increased in early-onset FGR in newborns with an extremely low body weight and high echogenicity of the periventricular zones, and reduced in late-onset FGR in newborns with IP, hyperbilirubinemia, intraventricular hemorrhage (IVH) and cerebral cysts. A prognostic model (AUC = 1; cutoff—0.5) was developed to assess the risk of IVH in newborns diagnosed with FGR based on the assessment of the OS markers (i.e., MDA + 4 HNE + CAT + GSH). A significant increase in the miR-127-3p expression was found in the plasma of newborns with NS (<32 GA; p ≤ 0.03 and >32 GA; p ≤ 0.009), IP (>32 GA; p ≤ 0.0001), and RDS (>32 GA; p ≤ 0.03). At the same time, the expression of miR-25-3p (p ≤ 0.03) was increased only in newborns with NS (>32 GA; p ≤ 0.03). The risk of developing IVH for premature newborns with IP (AUC = 0.8; cutoff—0.6) and NS (AUC = 0.68; cutoff—0.49) was assessed based on the miR-25-3p and miR-127-3p expression. Several key transcription factors were identified as the targets of studied miRNA since they are involved in the regulation of OS (NRF2), signaling and activation of the immune response (PRDM1, CCL26) and, also, inflammatory responses (NFKB1). The study of these miRNAs showed that they are involved in the modulation of processes leading to perinatal complications. Moreover, miR-127-3p is related to pro-inflammatory reactions and the formation of the macrophage phenotype in newborns with IP, NS, and RDS, while miR-25-3p is associated with an inhibition of macrophage migration and activation of antioxidant enzymes, which may prevent the development of oxidative damage in newborns with NS." @default.
• W4313502622 created "2023-01-06" @default.
• W4313502622 creator A5010766274 @default.
• W4313502622 creator A5021974137 @default.
• W4313502622 creator A5023424686 @default.
• W4313502622 creator A5039701466 @default.
• W4313502622 creator A5047915343 @default.
• W4313502622 creator A5064185691 @default.
• W4313502622 creator A5079401610 @default.
• W4313502622 creator A5086875186 @default.
• W4313502622 date "2022-12-21" @default.
• W4313502622 modified "2023-09-30" @default.
• W4313502622 title "Interrelation between miRNAs Expression Associated with Redox State Fluctuations, Immune and Inflammatory Response Activation, and Neonatal Outcomes in Complicated Pregnancy, Accompanied by Placental Insufficiency" @default.
• W4313502622 cites W1085629383 @default.
• W4313502622 cites W115161300 @default.
• W4313502622 cites W1272043828 @default.
• W4313502622 cites W1520130256 @default.
• W4313502622 cites W1924861336 @default.
• W4313502622 cites W1985844219 @default.
• W4313502622 cites W1996024251 @default.
• W4313502622 cites W2004055816 @default.
• W4313502622 cites W2007064404 @default.
• W4313502622 cites W2012435471 @default.
• W4313502622 cites W2024798078 @default.
• W4313502622 cites W2034492080 @default.
• W4313502622 cites W2035136686 @default.
• W4313502622 cites W2048572306 @default.
• W4313502622 cites W2049883415 @default.
• W4313502622 cites W2064540829 @default.
• W4313502622 cites W2066812556 @default.
• W4313502622 cites W2076715501 @default.
• W4313502622 cites W2093418220 @default.
• W4313502622 cites W2101518804 @default.
• W4313502622 cites W2104109524 @default.
• W4313502622 cites W2107277218 @default.
• W4313502622 cites W2117600285 @default.
• W4313502622 cites W2143360618 @default.
• W4313502622 cites W2155269196 @default.
• W4313502622 cites W2165954309 @default.
• W4313502622 cites W2192080449 @default.
• W4313502622 cites W2228061813 @default.
• W4313502622 cites W2269374145 @default.
• W4313502622 cites W2271087487 @default.
• W4313502622 cites W2284262522 @default.
• W4313502622 cites W2293304001 @default.
• W4313502622 cites W2322565284 @default.
• W4313502622 cites W2418071272 @default.
• W4313502622 cites W2433642980 @default.
• W4313502622 cites W2515504519 @default.
• W4313502622 cites W2519262228 @default.
• W4313502622 cites W2584837839 @default.
• W4313502622 cites W2593580368 @default.
• W4313502622 cites W2607405398 @default.
• W4313502622 cites W2625419520 @default.
• W4313502622 cites W2747424453 @default.
• W4313502622 cites W2765724553 @default.
• W4313502622 cites W2781218487 @default.
• W4313502622 cites W2787910888 @default.
• W4313502622 cites W2790086228 @default.
• W4313502622 cites W2885336652 @default.
• W4313502622 cites W2885432733 @default.
• W4313502622 cites W2897226698 @default.
• W4313502622 cites W2903300072 @default.
• W4313502622 cites W2906607137 @default.
• W4313502622 cites W2913285784 @default.
• W4313502622 cites W2941845020 @default.
• W4313502622 cites W2946172068 @default.
• W4313502622 cites W2977848620 @default.
• W4313502622 cites W2990826616 @default.
• W4313502622 cites W2996769041 @default.
• W4313502622 cites W3004427938 @default.
• W4313502622 cites W3012735630 @default.
• W4313502622 cites W3022010762 @default.
• W4313502622 cites W3024316689 @default.
• W4313502622 cites W3035857745 @default.
• W4313502622 cites W3042459926 @default.
• W4313502622 cites W3092455145 @default.
• W4313502622 cites W3110925142 @default.
• W4313502622 cites W3123931809 @default.
• W4313502622 cites W3131190077 @default.
• W4313502622 cites W3135020274 @default.
• W4313502622 cites W3160397630 @default.
• W4313502622 cites W3196215077 @default.
• W4313502622 cites W3198257974 @default.
• W4313502622 cites W3199510676 @default.
• W4313502622 cites W3217448188 @default.
• W4313502622 cites W4200439622 @default.
• W4313502622 cites W4211194784 @default.
• W4313502622 cites W4245575456 @default.
• W4313502622 cites W4246248105 @default.
• W4313502622 cites W4285744065 @default.
• W4313502622 cites W969915667 @default.
• W4313502622 doi "https://doi.org/10.3390/antiox12010006" @default.
• W4313502622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36670868" @default.
• W4313502622 hasPublicationYear "2022" @default.
• W4313502622 type Work @default.
• W4313502622 citedByCount "1" @default.
• W4313502622 countsByYear W43135026222023 @default.

• next